Related Experiment Video

Updated: Mar 7, 2026

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

16.2K

Structural interface between LRRK2 and 14-3-3 protein

Loes M Stevers1, Rens M J M de Vries1, Richard G Doveston1

  • 1Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, The Netherlands.

The Biochemical Journal
|February 17, 2017
PubMed

Insights

Parkinson's disease mutations disrupt the 14-3-3 protein binding to leucine-rich repeat protein kinase 2 (LRRK2). Understanding this complex interaction is key for developing new Parkinson's disease treatments.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Mutations in leucine-rich repeat protein kinase 2 (LRRK2) are linked to Parkinson's disease (PD).
  • Impaired binding of 14-3-3 proteins to LRRK2 is a common feature of PD-relevant mutations.
  • This disrupted interaction correlates with increased LRRK2 kinase activity and downstream pathological events in PD.

Purpose of the Study:

  • To investigate the complex binding interaction between 14-3-3 proteins and leucine-rich repeat protein kinase 2 (LRRK2).
  • To characterize the multivalent nature of the 14-3-3/LRRK2 interaction.
  • To provide insights into potential therapeutic strategies targeting this interaction for Parkinson's disease treatment.

Main Methods:

  • Biochemical assays were employed to study protein interactions.
  • Crystal structures were determined to visualize the binding interface.
  • Analysis of multivalent binding characteristics between 14-3-3 and LRRK2.

Main Results:

  • Characterization of the multivalent binding between 14-3-3 proteins and LRRK2.
  • Detailed structural insights into the interaction interface.
  • Understanding how PD-relevant mutations affect this binding.

Conclusions:

  • The interaction between 14-3-3 and LRRK2 is complex and multivalent.
  • This interaction is a promising target for Parkinson's disease drug development.
  • Further research into this binding mechanism could lead to novel therapeutic interventions.
Keywords:
Parkinson's diseasecrystallographyprotein–protein interactions

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

10.5K
Assaying the Kinase Activity of LRRK2 in vitro06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

23.0K

Related Concept Videos

Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
6.9K
Directing Proteins to the Rough Endoplasmic Reticulum01:34

Directing Proteins to the Rough Endoplasmic Reticulum

The organelle-specific signaling sequences direct proteins synthesized in the cytosol to their final destination like ER, mitochondria, peroxisomes, etc. Some of the proteins directed to ER are then trafficked via vesicles to other organelles within the cell or the extracellular environment through the Golgi complex. For example, the rough ER synthesizes soluble proteins for transportation to the lysosomes or secretion out of the cell. It can also synthesize transmembrane proteins that can...
18.1K
Regulation of Nuclear Protein Sorting01:45

Regulation of Nuclear Protein Sorting

Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
3.4K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
3.1K
Protein Modifications in the RER01:26

Protein Modifications in the RER

Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
7.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K